Clinical trial
Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia
NCT00037596 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00037596 |
|---|---|
| Title | Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia |
| Official title | A Dose Ranging Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) Given in Combination With Cytarabine in Relapsed or Refractory Patients and Alder De Novo Patients With Acute Myeloid Leukemia. |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | Gemtuzumab Ozogamicin, cytarabine. |
| Start date | Aug 1, 2000 |
| Primary completion | Apr 1, 2003 |
| Completion | Apr 1, 2003 |
| First posted | May 20, 2002 |
| Last update posted | Feb 13, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: